This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Nov 1;40(31):3564-3568.

doi: 10.1200/JCO.22.00859. Epub 2022 Jun 9.

Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?

Maurice Pérol¹, Aurélie Swalduz¹

Affiliations

PMID: 35679525
DOI: 10.1200/JCO.22.00859

Editorial

Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?

Maurice Pérol et al. J Clin Oncol. 2022.

. 2022 Nov 1;40(31):3564-3568.

doi: 10.1200/JCO.22.00859. Epub 2022 Jun 9.

Authors

Maurice Pérol¹, Aurélie Swalduz¹

Affiliation

¹ Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.

PMID: 35679525
DOI: 10.1200/JCO.22.00859

No abstract available

PubMed Disclaimer

Comment on

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
Solomon BJ, Bauer TM, Ignatius Ou SH, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Solomon BJ, et al. J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605188 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information